Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $61.30.

Several analysts recently issued reports on IMCR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a report on Thursday, January 22nd. UBS Group set a $55.00 target price on Immunocore and gave the company a “buy” rating in a research note on Wednesday, January 7th. Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, February 4th. Finally, Mizuho set a $38.00 target price on shares of Immunocore in a research note on Thursday, February 19th.

Insider Transactions at Immunocore

In related news, insider David M. Berman sold 5,965 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $192,967.75. Following the sale, the insider directly owned 5,859 shares in the company, valued at $189,538.65. This trade represents a 50.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Leger Tina Amber St sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $32,350.00. Following the completion of the sale, the insider directly owned 1,119 shares of the company’s stock, valued at approximately $36,199.65. This represents a 47.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 19,137 shares of company stock worth $619,082. Company insiders own 10.40% of the company’s stock.

Institutional Trading of Immunocore

Several institutional investors have recently modified their holdings of the company. Bellevue Group AG raised its holdings in shares of Immunocore by 99.9% in the 2nd quarter. Bellevue Group AG now owns 2,441,830 shares of the company’s stock worth $76,625,000 after purchasing an additional 1,220,036 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of Immunocore by 40.8% in the second quarter. Primecap Management Co. CA now owns 3,771,474 shares of the company’s stock valued at $118,349,000 after buying an additional 1,092,824 shares in the last quarter. BVF Inc. IL acquired a new stake in shares of Immunocore during the 2nd quarter valued at $32,142,000. Millennium Management LLC boosted its stake in shares of Immunocore by 334.3% during the 3rd quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock worth $45,993,000 after acquiring an additional 974,463 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in shares of Immunocore in the 4th quarter worth $20,305,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Trading Down 5.3%

Immunocore stock opened at $31.93 on Friday. Immunocore has a 1 year low of $23.15 and a 1 year high of $40.71. The firm’s 50-day moving average is $33.17 and its 200-day moving average is $34.32. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.01 and a current ratio of 4.04. The company has a market cap of $1.61 billion, a P/E ratio of -45.61 and a beta of 0.78.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.32). Immunocore had a negative return on equity of 9.20% and a negative net margin of 8.88%.The business had revenue of $104.48 million for the quarter, compared to analyst estimates of $145.48 million. During the same quarter last year, the company earned ($0.47) EPS. Immunocore’s revenue was up 24.3% compared to the same quarter last year. On average, equities analysts expect that Immunocore will post -0.94 earnings per share for the current year.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.